Skip to main content

Table 3 Summarised ceCT results in discordant cases with incremental ceCT abnormalities that were likely true positive

From: Does addition of a diagnostic contrast-enhanced CT to a contemporaneous PET/CT provide incremental value in patients for restaging of colorectal carcinoma?

Case

PET/CT finding

ceCT finding

Followup

Anticipated impact of ceCT on management

3.1

Complete metabolic response in liver metastases 2 weeks post-6 cycles of chemotherapy

Improved but persistent liver lesions (largest 13 mm)

True positive.

(Small volume residual viable tumour in hepatic resection)

No change

3.2

No abnormal FDG uptake in peripancreatic nodal mass

Peripancreatic mass (37 mm)

Repeat PET 2 months later, peripancreatic nodal mass became FDG avid. (Original PET performed 1 month post completion of chemoradiotherapy)

Appropriate change

3.3

No abnormal FDG uptake

Locoregional nodal disease (N1)

Histology of resected primary showed locoregional nodal disease (PET performed post neoadjuvant chemotherapy).

No change

3.4

No metastases

Locoregional nodal disease (N1)

Nodes positive for metastases on primary excision specimen. (PET performed post neoadjuvant chemoradiotherapy)

No change